Inotuzumab ozogamicin
- Generic Name
- Inotuzumab ozogamicin
- Brand Names
- Besponsa
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 635715-01-4
- Unique Ingredient Identifier
- P93RUU11P7
- Background
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting ...
- Indication
Indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).
- Associated Conditions
- Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
- Associated Therapies
- -
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT01363297
- Locations
- 🇺🇸
Stanford Unversity Cancer Clinical Trials Office, Palo Alto, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
🇺🇸Stanford Unversity Hospital and Clinics, CTRU, Palo Alto, California, United States
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 338
- Registration Number
- NCT01232556
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services, Los Angeles, California, United States
🇺🇸University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00562965
- Locations
- 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
🇺🇸Facey Medical Group, Mission Hills, California, United States
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 119
- Registration Number
- NCT00299494
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.